News

Targeted Oncology19m
Long-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML
New long-term data highlights the effectiveness and safety of ivosidenib with azacitidine for treating IDH1-mutated AML, ...
Targeted Oncology34m
TRANSFORM Trial: Clinical Perspectives in Liso-Cel CAR T-Cell Therapy for Second-Line R/R LBCL
An expert discusses that while the liso-cel trial did not show a statistically significant overall survival benefit—likely ...